Beigene

This study tested an oral drug called zanubrutinib in 55 Japanese patients with advanced B-cell blood cancers that had returned or stopped responding to prior treatment. The main goals were to check the drug's safety, how the body processes it, and to see if it could shrink tumor…

This study tested whether adding a new drug called gimistotug (BGB-A445) to other investigational treatments could help people with advanced non-small cell lung cancer whose previous treatments stopped working. The trial involved 35 participants who had already received standard …

This large, completed study tested if a new drug called tislelizumab helps people with advanced liver cancer live longer than the standard treatment, sorafenib. It involved 684 adults whose cancer could not be removed by surgery and who had not received prior drug treatment for i…

This study tested a drug called zanubrutinib for people with several types of B-cell lymphoma who had to stop their previous treatments due to bad side effects. The main goal was to see if zanubrutinib caused fewer or less severe side effects for these patients. Researchers also …

This early-phase study tested the safety and best dose of a new drug called BGB-10188. It was given alone or combined with other cancer drugs to 97 patients with advanced blood cancers or solid tumors that had returned or stopped responding to prior treatments. The main goal was …

This study tested whether adding a pill called zanubrutinib to an existing drug (obinutuzumab) works better than the existing drug alone for adults with follicular lymphoma that has come back or stopped responding to prior treatments. It involved 217 participants who were randoml…

This study tested whether a pill called zanubrutinib could help adults with a specific type of aggressive lymphoma that had returned or stopped responding to prior treatments. The trial focused on people whose cancer had a particular genetic change (CD79B mutation). Participants …

This study tested an immunotherapy drug called tislelizumab in 46 people whose classical Hodgkin lymphoma had come back or stopped responding to prior treatments. The main goal was to see how many patients' tumors shrank or disappeared after receiving the drug. Participants recei…

This early-stage study tested the safety and best dose of a new two-drug immunotherapy combination (BGB-A445 plus tislelizumab) in 204 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see how much of the drugs patients cou…

This early-stage study tested the safety and initial effects of combining two oral drugs, BGB-283 and PD-0325901, in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug combination could…

This early-stage study tested the safety and initial effectiveness of two different drug combinations for people with an aggressive type of lymphoma (DLBCL) that has returned or stopped responding to prior treatment. The trial involved 53 patients who were not eligible for stem c…

This study tested whether giving the immunotherapy drug tislelizumab before surgery could help people with early-stage colorectal cancer that has specific genetic features (called MSI-H or dMMR). The goal was to see if the drug could shrink or even eliminate the tumor before it w…

This study tested a personalized approach to treat esophageal cancer before surgery. Doctors used PET scans to guide whether patients received immunotherapy plus chemotherapy alone or with added radiation. The goal was to shrink tumors completely before surgical removal, potentia…

This study tested new combinations of immunotherapy drugs (BGB-A425, LBL-007, and tislelizumab) in patients with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if blocking multiple immune system 'brakes' at once is safe and can help …

This study tested whether giving a drug called tislelizumab, either alone or combined with other drugs, before surgery could help shrink tumors in people with early-stage lung cancer. It involved 121 Chinese adults whose cancer could be removed by surgery. The main goal was to se…

This study tested whether adding a new drug called ociperlimab to an existing immunotherapy (tislelizumab) and standard chemotherapy was more effective and safe for people with advanced non-small cell lung cancer that had not been treated before. It involved 272 participants whos…

This study aimed to understand how two common medications (phenytoin and itraconazole) affect the way the body processes an experimental drug called BGB-16673. It involved 37 healthy adult volunteers who took BGB-16673 alone and then alongside the other medications. The main goal…

This early-stage study tested how the body absorbs two different versions of an experimental pill called BGB-43395. It involved 51 healthy adults to see how much of the drug gets into the bloodstream and if taking it with food makes a difference. The main goal was to gather basic…

This was the first study to test a new drug called BGB-23339 in humans. It involved 92 healthy volunteers to check if the drug is safe, what side effects it might cause, and how the body absorbs and processes it. The study also looked at whether taking the drug with food changes …